Study of S-1 as Second Line Treatment on Advanced Pancreatic Cancers
Status:
Unknown status
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
A randomized , open-label, multicenter, phase II study to compare the efficacy of S-1 and S-1
plus Leucovorin as second line treatment on gemcitabine-refractory patients with inoperable
or advanced pancreatic cancers，investigate the correlation between efficacy and the
expressions of thymidylate synthase, dihydropyrimidine dehydrogenase and orotate
phosphoribosyltransferase
Phase:
Phase 2
Details
Lead Sponsor:
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences